{"id":"53aed3b1-d0e9-5925-acf7-235a8cab52bb","stable_key":"22527305-af1f-536a-b419-7e73f08cc3ec:luteolin-ck2-human","predicate":"inhibits","statement":"Luteolin inhibited reconstituted human CK2 alpha-prime/beta holoenzyme, IC50 0.86 micromolar.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"bfbdb6d2-dbb1-5a4c-a9c8-c06d3ce0f0b6","mechanism_event_label":"A measured kinase effect uses a defined human subunit combination.","subject":{"id":"80472c4b-ecc2-52e3-a766-f8463294774f","slug":"luteolin","display_name":"Luteolin / 3′,4′,5,7-tetrahydroxyflavone","entity_type_key":"small_molecule"},"object":{"id":"8c3eb79c-4a30-5a53-a409-e1c4a4cea639","slug":"human-ck2-alpha-prime-holoenzyme","display_name":"Human CK2 alpha-prime/beta reconstituted holoenzyme","entity_type_key":"protein_complex"},"evidence_count":1,"mechanism_event":{"id":"bfbdb6d2-dbb1-5a4c-a9c8-c06d3ce0f0b6","stable_key":"22527305-af1f-536a-b419-7e73f08cc3ec:luteolin-ck2-human-event","event_type":"observed_relationship","label":"A measured kinase effect uses a defined human subunit combination.","description":"Luteolin inhibited reconstituted human CK2 alpha-prime/beta holoenzyme, IC50 0.86 micromolar.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"80472c4b-ecc2-52e3-a766-f8463294774f","slug":"luteolin","display_name":"Luteolin / 3′,4′,5,7-tetrahydroxyflavone","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8c3eb79c-4a30-5a53-a409-e1c4a4cea639","slug":"human-ck2-alpha-prime-holoenzyme","display_name":"Human CK2 alpha-prime/beta reconstituted holoenzyme","entity_type_key":"protein_complex"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"a834a865-12fd-597a-85cf-c0a5571a4b82","slug":"csnk2a2","display_name":"Human CK2 alpha-prime / CSNK2A2","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"8b31ccee-d086-5cab-955f-9f14793b2255","slug":"csnk2b","display_name":"Human CK2 beta / CSNK2B","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"58b974f1-d389-5bf6-81cd-889c44442c42","slug":"atp","display_name":"ATP","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Recombinant human alpha-prime plus beta; radiolabeled ATP transfer.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Assay potency is not an oral therapeutic concentration.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"luteolin","display_name":"Luteolin / 3′,4′,5,7-tetrahydroxyflavone","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A measured kinase effect uses a defined human subunit combination.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19197122/","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"d007d4d1-8ecc-5f5c-8301-143f235a187b","evidence_kind":"source_excerpt","locator":"Lines 332-338","start_line":332,"end_line":338,"excerpt":"## luteolin-ck2-human\nA measured kinase effect uses a defined human subunit combination.\nLuteolin inhibited reconstituted human CK2 alpha-prime/beta holoenzyme, IC50 0.86 micromolar.\nModel: Recombinant human alpha-prime plus beta; radiolabeled ATP transfer.\nLimitations: Assay potency is not an oral therapeutic concentration.\nEvidence access: Primary abstract\nStructure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19197122/","model_system":"Recombinant human alpha-prime plus beta; radiolabeled ATP transfer.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"26337a08-5cee-5cee-900e-e6d3e26ac6e4","stable_key":"import-22527305-af1f-536a-b419-7e73f08cc3ec","title":"Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"fd6ea0b1cef8d1c9965270494bfa815de14f679044f0b5d5d7bbf4904630ad76","revision_id":"c9a3dd80-c7e6-5fb4-bc91-8db265e7c8de","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}